---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-009481"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2022-02-25T23:59:59+00:00"
generated_at: "2026-06-27T04:18:53.619888+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Helix enters $15M convertible loan with MoonLake; rollover option into PIPE

## Summary
- Cormorant Private Healthcare Fund IV lends MoonLake $15M interest-free, unsecured, for general corporate purposes pending business combination.
- Loan matures 2 days after deal closing or June 30, 2022; may roll over into Cormorant's $27.5M PIPE commitment.
- If deal terminates, loan converts into MoonLake shares; subordinated to all creditors but senior to existing subordinated loans.
- Proceeds cannot be used to repay existing $15M loan from Biotechnology Value Funds.

## SEC filing metadata
- accession: 0001213900-22-009481
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2022-02-25T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390022009481/0001213900-22-009481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390022009481/ea156204-8k_helixacq.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-009481
- JSON: https://secwatch.observer/filing/0001213900-22-009481.json
- Plain text: https://secwatch.observer/filing/0001213900-22-009481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.